Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

In 2023, there were an estimated 68,890 people living with hepatitis C in Australia, down 58% from 162,590 at the end of 2015 ...

Members of the West Virginia First Foundation circumvented its typical proposal process to allocate $20 million to Marshall ...

In a new study, opioid addicts experienced structural and functional changes in specific regions of their brains.

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. The German pharma acquired rights to the TRPV1 agonist also known as MTX-071 last year when it ...

This means treatments are designed to target various pain receptors beyond opioid receptors in the spinal cord ... pain ...

Former world leaders skewer the failures of prohibition. “If we were designing policies from scratch, this model would look ...

After her son’s death, Melissa Etheridge turned her grief into advocacy by creating a foundation to support new research into ...

Opioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the ...

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro-inflammatory mediators. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with ...

Years of therapy and treatment followed ... Opioids increase dopamine by binding to opioid receptors, which leads to reduced inhibition of dopamine release in the brain’s reward areas.